Symbol="IMMX"
AssetType="Common Stock"
Name="Immix Biopharma Inc"
Description="Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, is dedicated to the development of various tissue-specific therapies in oncology and inflammation in the United States and Australia. The company is headquartered in Los Angeles, California."
CIK="1873835"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="11400 WEST OLYMPIC BLVD., SUITE 200, LOS ANGELES, CA, US"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="32085000"
EBITDA="-11567278"
PERatio="None"
PEGRatio="None"
BookValue="0.813"
DividendPerShare="0"
DividendYield="0"
EPS="-0.97"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.417"
ReturnOnEquityTTM="-0.731"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.97"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="11"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="1.156"
EVToRevenue="-"
EVToEBITDA="-0.0128"
Beta="None"
num_52WeekHigh="3.29"
num_52WeekLow="0.68"
num_50DayMovingAverage="2.178"
num_200DayMovingAverage="1.986"
SharesOutstanding="16286800"
DividendDate="None"
ExDividendDate="None"
symbol="IMMX"
open="1.76"
high="1.99"
low="1.76"
price="1.97"
volume="93948.00"
latest_trading_day="2023-08-21"
previous_close="1.73"
change="0.24"
change_percent="13.8728%"
aroon_positive_momentum_days="30"
aroon_negative_momentum_days="0"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Buy Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="30"
Volume_recent_avg="241571"
Change_recent_avg="0.01"
Delta_recent_avg="0.19"
Variance_recent_avg="0.1"
Change_ratio_recent_avg="-0.04"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="positive"
Aroon_change="FALSE"
Aroon_momentum_positive="30"
Aroon_momentum_negative="70"
image_negative_thumbnail_id_1="1132"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0165.jpeg"
image_negative_thumbnail_id_2="141"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/05/MI_Finance_Negative_Landscape_0035.jpeg"
image_neutral_thumbnail_id_1="546"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0053.jpeg"
image_neutral_thumbnail_id_2="576"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0023.jpeg"
image_positive_thumbnail_id_1="647"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0061.jpeg"
image_positive_thumbnail_id_2="960"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0122.jpeg"
image_professor_thumbnail_id_1="1198"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0032.jpeg"
image_professor_thumbnail_id_2="1178"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0012.jpeg"
